HUTCHMED Announces the Closing of the Global Offering and the Primary Listing in Hong KongGlobeNewsWire • 06/30/21
HUTCHMED announces savolitinib approved in China for patients with lung cancer with MET exon 14 skipping alterationsGlobeNewsWire • 06/22/21
HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda® in China) for Advanced Pancreatic Neuroendocrine TumorsGlobeNewsWire • 06/18/21
HUTCHMED Highlights Clinical Data to be Presented at the Upcoming ASCO21 Virtual Scientific ProgramGlobeNewsWire • 05/20/21
Save the date: HUTCHMED to Host Company Update on R&D, Commercial and ASCO Data For Analysts and InvestorsGlobeNewsWire • 05/17/21
HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine TumorsGlobeNewsWire • 05/03/21
HUTCHMED Initiates Phase II Registration Study of HMPL-689 in Patients with Follicular Lymphoma and Marginal Zone Lymphoma in ChinaGlobeNewsWire • 04/29/21
HUTCHMED Announces US$100 Million Equity Investment by Baring Private Equity AsiaGlobeNewsWire • 04/08/21
HUTCHMED Initiates International Phase I Trials of IDH1/2 Dual Inhibitor in Patients with Advanced Solid Tumors or Hematological MalignanciesGlobeNewsWire • 03/29/21
HUTCHMED Enters Agreement to Divest Non-Core OTC Joint Venture for US$169 MillionGlobeNewsWire • 03/24/21
Hutchison China, BeiGene Start Testing Surufatinib/Tislelizumab Combo In Solid Tumor StudyBenzinga • 03/24/21
HUTCHMED Initiates a Phase Ib/II Trial of Surufatinib in Combination with Tislelizumab in Patients with Advanced Solid TumorsGlobeNewsWire • 03/24/21
Hutchison China MediTech Limited's (HCM) CEO Christian Hogg on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/04/21
Hutchison China MediTech Limited Reports 2020 Full Year Results and Provides Business Updates and Evolves Corporate IdentityGlobeNewsWire • 03/04/21
Chi-Med and Inmagene Announce Strategic Partnership to Develop and Commercialize Portfolio of Drug Candidates for Immunological DiseasesGlobeNewsWire • 01/11/21
Chi-Med Announces the NMPA Approval of Surufatinib (Sulanda® in China) for Non-Pancreatic Neuroendocrine TumorsGlobeNewsWire • 12/30/20